Diagonal Therapeutics’ Post

#Columbus-based #ClarametyxBiosciences secures $33M in series A round funding. The proceeds from the round will enable the company to accelerate efforts across its pipeline, including specifically to evaluate the potential of Clarametyx’s lead #therapeutic candidate. In addition to new #support from the CF Foundation, the Series A financing was led by the Ohio Innovation Fund, with participation from current investors Nationwide Children’s Hospital, Rev1 Ventures, JobsOhio Growth Capital, C Bio Investors and 1776 Fund. CMTX-101 to combat infection in people with cystic #fibrosis (CF), a progressive, genetic disease that affects the #lungs, #pancreas and other organs. Clarametyx Biosciences is #combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic #intervention. Clarametyx Biosciences Ohio Innovation Fund Nationwide Children's Hospital Rev1 Ventures To share your startup story write us on - contact@startuprise.io #clarametyxbioscience #funding #startup

#Torino-based #Resalis secures €10 million in series A round #funding. This round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors. The proceeds will be used to #initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program, RES-010, in obesity. RES-010 is a non-coding RNA-based #compound designed to provide a disease-modifying approach in obesity with longer-lasting weight reduction and the ability to extend treatment #durability in combination with approved therapeutics, such as GLP-1 receptor #agonists. Resalis Therapeutics’ transformative #metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. Resalis Therapeutics Sunstone Life Science Ventures Claris Ventures Pietro Puglisi Claus Andersson Alessandro Toniolo To share your startup story write us on - contact@startuprise.co.uk #resalistherapeutics #funding #eustartup

⭐Could we be on the brink of a new era in Inflammatory Bowel Disease treatment? ⭐ The brilliant minds at Spyre Therapeutics, led by dynamic founders!❗️ This forward-thinking biotech startup, nestled in the heart of San Francisco, is pushing boundaries and reimagining the future of IBD treatment. Find out how their pioneering antibody therapies might just revolutionize the way we approach this chronic and debilitating disorder.🔬 Only on https://lnkd.in/eBP2qTBm Please share to spread the word about the astonishing progress being made in the biotech field today! #biotech #IBD #innovation #startups #therapeutics

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> A new obesity biotech; UroGen aims to raise $107M: Plus, news about Otsuka, Ionis, Ability Biologics, Santhera, Mustang Bio and Vaxart: New biotech joins obesity race: Supercede Therapeutics raised an undisclosed seed round from an unnamed investor to help it develop an oral obesity medicine that goes after the same target as Eli Lilly’s bimagrumab, which is being developed as an IV infusion and is in Phase 2. Supercede licensed molecules from China’s Fudan University and East China Normal University, CEO Ilan Zipkin told Endpoints News. Zipkin was previously a partner at Aditum Bio, the venture firm that created Versanis Bio, which Lilly bought last year to get bimagrumab. Years ago, Zipkin said he thought about creating a biotech venture fund called Supercede but didn’t follow through with it. He liked the name and kept it for the new startup. — Kyle LaHucik UroGen prices $107.5M offering: The cancer biotech plans to sell shares at $17.50 a piece, about 75 cents lower than its closing price on Monday. UroGen’s shares $URGN were down about 9% on Tuesday morning. Last week, UroGen disclosed more data from a Phase 3 bladder cancer study. — Kyle LaHucik Otsuka expands rights to Ionis drug: The Japanese drugmaker is now licensing donidalorsen, Ionis’ hereditary angioedema drug candidate, in Asia-Pacific for $20 million upfront. It made a European licensing pact for the drug last year. — Kyle LaHucik Ability Biologics raises $18M seed round: The Canadian biotech is working on antibody medicines for immune-related diseases and cancer. Investors include fellow Canadian firm Amplitude Ventures, Charles River Laboratories, Alexandria Venture Investments and others. — Kyle LaHucik Santhera gets up to $77M: The Swiss biotech said the up to CHF 69 million deal comes by way of royalty and debt financings. Santhera’s cash runway could now extend into the first half of 2026. — Kyle LaHucik Mustang Bio shares new CAR-T data: The company announced Monday that nine of ten patients with a rare blood cancer known as Waldenström’s macroglobulinemia who received its CAR-T therapy responded to treatment, with three seeing all signs of their cancer disappear. Its stock $MBIO quintupled in value on Monday, though its shares are still down about 20% since the beginning of the year.   — Lei Lei Wu Vaxart is developing an avian flu vaccine. — Jaimy Lee #lucidquest #genetherapy #celltherapy

Chasing CAR-T, biotech finds its next gold rush in autoimmune disease Venture capitalists are plowing money into drug development in the field Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. But there’s one field that has seen an even more significant amount of activity: autoimmune diseases. Companies that are developing new medicines for autoimmune conditions, as well as other immune system disorders, have brought in more money and closed more deals so far this year than most other areas, including the cardiometabolic field, data from investment bank Oppenheimer show. (Oncology remains king when it comes to investment, driven in part by interest in new approaches like radiopharmaceuticals). https://lnkd.in/eeuz7-Md

#fundingalert 💼Company: Allegria Therapeutics 💰Funding: USD3.5Million ⚡Round: Seed 👥Investors: Forty51 Ventures. Allegria Therapeutics was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases. With the current financing, ALLEGRIA will progress a differentiated portfolio of proprietary therapeutic approaches around targets that selectively modulate mast cells to more effectively address patients' needs. Maria Van Dongen Read more - https://lnkd.in/g2Xn8BwD To share your startup story write us on - contact@startuprise.co.uk #AllegriaTherapeutics #inflammatorydiseases #funding #news #fundingnews #startup #startuprise #startupnews

CAR-T’s second act? Venture capital is flowing into companies developing autoimmune treatments, fueled largely by the promise of repurposing CAR-T to treat lupus and other autoimmune diseases. While CAR-T has been life-changing for thousands of patients suffering from blood cancers, drug companies have struggled to manufacture them quickly enough to meet demand. Will the next generation of treatments suffer the same problem? Investors obviously see promise, and there are hopeful signs on the horizon: a phase 1 trial for a lupus treatment BMS says can be produced in less than a week and allogeneic therapies under development that would enable drugmakers to manufacture treatments using donor cells instead of patient ones.

👀Looking forward to OBN (UK) Ltd’s BioSeed event happening on 11 June, where three of our portfolio companies will be presenting. #BioSeed is OBN's flagship healthcare startup accelerator event, nurturing and showcasing cutting-edge innovations from our member companies. Here are the three o2h Ventures portfolio companies presenting: - Stratosvir Limited is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. - Clotprotect Tx is developing first-in-class small molecule CP101 which is a direct plasma inhibitor, which will help in improving the bleeding and survival outcomes compared to SOC to tranexamic acid. This has the potential to transform thrombosis management and save countless lives. - CardiaTec Biosciences is at the forefront of cardiac care innovation with their AI-powered software that enables early detection and management of cardiovascular diseases, improving patient outcomes and quality of life. Excited to see these innovative biotech companies showcased at BioSeed! 🚀

We are pleased to announce we are doubling down on our initial partnership with Healx, the AI-enabled clinical-stage biotech company specialising in treatments for rare diseases, to co-lead their $47m Series C today alongside R42 Group. 💊 This comes at an exciting time for Healx, who are also announcing US FDA Clearance of Phase 2 clinical trials for the treatment of neurofibromatosis Type 1 (NF1), which is a rare genetic disorder affecting 1 in 2,500 people. Patients with NF1 develop multiple benign and malignant tumours that grow along nerves and can cause pain and disfigurement, reducing life expectancy and quality of life. 🌳 Founded in Cambridge in 2014 by Tim Guilliams, Ph.D and David Brown, Ph.D, Healx harnesses AI to increase speed and efficiency of the R&D process for discovering new treatments for rare diseases. 💰 Remarkably, the commercial model for traditional drug discovery takes 12–15 years with a price tag of between $2–3bn, and a failure rate of 95%. There are approximately 7,000 rare diseases in the world, with 400 million people impacted - half of which are children. Many of these can be chronic or life threatening. Only 5% have a treatment. 🤖 Sitting behind all of this progress is Healnet - Healx’s proprietary novel AI drug discovery engine that combines deep scientific expertise and extensive proprietary data, and allows the team to move towards clinical trials 80% faster, 80–90% cheaper and with a greater chance of success than conventional drug discovery methods. ❤️ Beyond the statistics, however, this approach can change - and save - lives. We’re exceptionally proud of what Tim Guilliams, David and the team at Healx have achieved so far and we’re humbled to be part of their next chapter. Read more here: https://lnkd.in/eDFTj8en

It's time to Dish!! 🧫🔬 The latest full episode of our new video series, 'The Dish with Johannes' just dropped on our Youtube channel! Full episode here 👉 https://lnkd.in/eKDtwVZ6 In this episode, Johannes Fruehauf sits down with Luca Giani, CEO & Co-Founder of Ilios Therapeutics journey into the world of #biotech, Ilios's novel approach to #neurodegenerative diseases, and the simple question that started it all. 💡 #TheDish #innovation #ALS #Alzheimers #CEO #founder #startup